PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Adlai Nortye Biopharma Co., Ltd.

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).

Explore the portfolio See the ranking
5
Total patents granted
6
CPC technology areas
14.0
Avg claims per patent
-
5-year filing velocity

The verdict

Adlai holds 5 US patents across 6 technology areas, rank #44,401 of 50,000 tracked assignees.

#44,401
of 50,000 US assignees by volume
Top 29%
by Innovation Score (43.3/100)
14.0
avg claims per patent

Portfolio overview

Adlai Nortye Biopharma Co., Ltd. has been granted 5 US utility patents between 2021 and 2025, placing Adlai Nortye Biopharma Co., Ltd. at rank #44,401 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.0 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a Foreign Corporation, Adlai Nortye Biopharma Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Adlai sits between Adhark, Inc. (5 patents, rank #44,397) and Advanced Composite Products & Technology, Inc. (5 patents, rank #44,405) - the closest US assignees by grant volume. The composite Innovation Score of 43.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Adlai Nortye Biopharma Co., Ltd.'s 14.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Adlai Nortye Biopharma Co., Ltd. against peers pursuing similar technology classes.

Who files at Adlai's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Adlai holds 5 patents at rank #44,401, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Adlai

By rank, the assignees closest to #44,401 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Adlai's primary technology class.

Adlai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2021202320242025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Adlai Nortye Biopharma Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 20.0%
2023 1 20.0%
2024 2 40.0%
2025 1 20.0%

Which technologies does Adlai Nortye Biopharma Co., Ltd. patent most?

Top 6 of 6 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard

Where it ranks

Overall rank by patents

#44,401

Across all tracked assignees

Innovation Score

43.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Adlai Nortye Biopharma Co., Ltd. hold?
Adlai Nortye Biopharma Co., Ltd. holds 5 US granted patents filed between 2021 and 2025, spanning 6 technology areas.
What is Adlai Nortye Biopharma Co., Ltd.'s Innovation Score?
Adlai Nortye Biopharma Co., Ltd. has an Innovation Score of 43.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Adlai Nortye Biopharma Co., Ltd. focus on?
Adlai Nortye Biopharma Co., Ltd.'s top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 3 patents. The company has filed patents in 6 CPC subclasses total.
Is Adlai Nortye Biopharma Co., Ltd.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Adlai Nortye Biopharma Co., Ltd..
What does claim depth mean for Adlai Nortye Biopharma Co., Ltd.'s patents?
Adlai Nortye Biopharma Co., Ltd.'s patents average 14.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Adlai Nortye Biopharma Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Adlai's 5 grants land it in the top 29% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Adlai ranks #44,401 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C07D - see who else leads that technology area. C07D leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.